Gilead Sciences (GILD) 106.86 $GILD
Alkermes Completes Enrolment for Phase II ALKS 3831 Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 04, 5:10PM CDT
Alkermes (ALKS) completed enrolling patients in a study on ALKS 3831.
Most active Nasdaq-traded stocks
AP - Thu Sep 04, 4:57PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
Final Glance: Biotechnology companies
AP - Thu Sep 04, 4:57PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were down at the close of trading:
Alexion Pharmaceuticals' Soliris Wins NICE Backing for aHUS - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 04, 4:00PM CDT
Alexion's (ALXN) Soliris is highly effective for treating aHUS as per NICE.
3 Reasons Bristol-Myers Squibb's Stock Could Fall
George Budwell, The Motley Fool - Motley Fool - Thu Sep 04, 3:42PM CDT
This has been a year of major changes for Big Pharma. As the so-called patent cliff has started to peak, we've seen a number of companies make huge acquisitions, push promising new drugs into regulatory review, and even move to change locales to...
J&J Ebola Vaccine Gets Funding, Development to Pick Pace - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 04, 2:37PM CDT
Johnson & Johnson (JNJ) announced that its Ebola vaccine development process will be fast-tracked.
Midday Glance: Biotechnology companies
AP - Thu Sep 04, 12:16PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Market Maker Surveillance Report. GILD, GE, SLM, ACHN, WU, SREV, Bullishly Biased Price Friction For Wednesday, September 3rd 2014
M2 - Thu Sep 04, 10:02AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Wednesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Wednesday there were 4918 companies with "abnormal" market making, 2306 companies with positive Friction Factors and 2830 companies with negative Friction Factors. Here is a list of the top companies with Abnormal Price Friction (bullish bias) in their stock prices. This means that there was more selling than buying in the stocks and their stock prices rose. GILEAD SCIENCES, INC. (NASDAQ:GILD), General Electric Co (NYSE:GE), SLM Corp (NASDAQ:SLM), Achillion Pharmaceuticals Inc (NASDAQ:ACHN), Western Union Co (NYSE:WU), SERVICESOURCE INTERNATIONAL INCORPORATED (NASDAQ:SREV). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
Early Glance: Biotechnology companies
AP - Thu Sep 04, 9:27AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Rexahn Pharmaceuticals (RNN) Jumps: Stock Rises 9.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 04, 8:39AM CDT
Rexahn Pharmaceuticals, Inc. (RNN) was a big mover last session, as its shares rose almost 10% on the day.
Upcoming Event, Drug Approval, Technical Updates, and Research Grant - Research Reports on Gilead, Pfizer, AbbVie, Express Scripts and Thermo Fisher
PR Newswire - Thu Sep 04, 8:20AM CDT
Today, Analysts Review released its research reports regarding Gilead Sciences, Inc. (NASDAQ: GILD), Pfizer Inc. (NYSE: PFE), AbbVie Inc. (NYSE: ABBV), Express Scripts Holding Company (NASDAQ: ESRX) and Thermo Fisher Scientific Inc. (NYSE: TMO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6210-100free.
Exact Sciences Corp. (EXAS) in Focus: Stock Rises 6.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 04, 7:51AM CDT
Exact Sciences Corporation (EXAS) was a big mover last session, as its shares rose over 6% on the day.
3 Reasons Gilead Sciences, Inc.’s Stock Could Fall
Brian Orelli, The Motley Fool - Motley Fool - Thu Sep 04, 7:31AM CDT
Gilead Sciences ' stock is a trading at all-time highs, up more than 80% over the last year on the back of a very successful launch of the company's hepatitis C drug Sovaldi. A few weeks ago, I shared three reasons Gilead's stock could go even...
Roche's Cobas 6800/8800 Testing Systems Launched - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 03, 5:55PM CDT
Roche (RHHBY) announced that its cobas 6800/8800 systems -- two integrated and fully automated molecular testing systems for blood and plasma donor screening are commercially available in markets which accept the CE mark.
Infinity Pharma (INFI) Shares Skyrocket on Cancer Drug Partnership - Stocks in the News
Zacks Research Staff - Zacks Investment Research - Wed Sep 03, 5:47PM CDT
Shares of Infinity Pharma (INFI) are up more than 40 percent thanks to news of a partnership with AbbVie for a new cancer drug.
Sanofi Reports Positive Phase III Data on Dengue Vaccine - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 03, 5:40PM CDT
Sanofi (SNY) announced that a phase III efficacy study on its dengue vaccine candidate has met the primary endpoint.
New Managers Revive Thrivent Large Cap Growth Fund
at Investor's Business Daily - Wed Sep 03, 5:28PM CDT
Thrivent Large Cap Growth is a reminder of how new managers can herald a change in a mutual fund's fortune. David Francis and Darren Bagwell, now co-managers, took the helm of the $521 million portfolio on Oct. 1, 2011. In the three years prior to...
Three Stocks Top-Performing Funds Like: Facebook Baidu Gilead
at Investor's Business Daily - Wed Sep 03, 5:28PM CDT
The new buys list of top-performing funds the past three months showed some heavy buying of top-rated stocks. The nation's leading funds have been stocking up on medical issues, which fared well as the market resumed its uptrend in August. Large...
Arena Pharmaceuticals' APD811 Gets Orphan Drug Status - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 03, 4:20PM CDT
Arena Pharmaceuticals, Inc. announced that its pulmonary arterial hypertensioncandidate APD811 has received orphan drug status from the FDA.
Alkermes Completes Enrolment for Phase II ALKS 3831 Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 04, 5:10PM CDT
Alkermes (ALKS) completed enrolling patients in a study on ALKS 3831.
Most active Nasdaq-traded stocks
AP - Thu Sep 04, 4:57PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
Final Glance: Biotechnology companies
AP - Thu Sep 04, 4:57PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were down at the close of trading:
Alexion Pharmaceuticals' Soliris Wins NICE Backing for aHUS - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 04, 4:00PM CDT
Alexion's (ALXN) Soliris is highly effective for treating aHUS as per NICE.
3 Reasons Bristol-Myers Squibb's Stock Could Fall
George Budwell, The Motley Fool - Motley Fool - Thu Sep 04, 3:42PM CDT
This has been a year of major changes for Big Pharma. As the so-called patent cliff has started to peak, we've seen a number of companies make huge acquisitions, push promising new drugs into regulatory review, and even move to change locales to...
J&J Ebola Vaccine Gets Funding, Development to Pick Pace - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 04, 2:37PM CDT
Johnson & Johnson (JNJ) announced that its Ebola vaccine development process will be fast-tracked.
Midday Glance: Biotechnology companies
AP - Thu Sep 04, 12:16PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Market Maker Surveillance Report. GILD, GE, SLM, ACHN, WU, SREV, Bullishly Biased Price Friction For Wednesday, September 3rd 2014
M2 - Thu Sep 04, 10:02AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Wednesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Wednesday there were 4918 companies with "abnormal" market making, 2306 companies with positive Friction Factors and 2830 companies with negative Friction Factors. Here is a list of the top companies with Abnormal Price Friction (bullish bias) in their stock prices. This means that there was more selling than buying in the stocks and their stock prices rose. GILEAD SCIENCES, INC. (NASDAQ:GILD), General Electric Co (NYSE:GE), SLM Corp (NASDAQ:SLM), Achillion Pharmaceuticals Inc (NASDAQ:ACHN), Western Union Co (NYSE:WU), SERVICESOURCE INTERNATIONAL INCORPORATED (NASDAQ:SREV). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
Early Glance: Biotechnology companies
AP - Thu Sep 04, 9:27AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Rexahn Pharmaceuticals (RNN) Jumps: Stock Rises 9.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 04, 8:39AM CDT
Rexahn Pharmaceuticals, Inc. (RNN) was a big mover last session, as its shares rose almost 10% on the day.
Upcoming Event, Drug Approval, Technical Updates, and Research Grant - Research Reports on Gilead, Pfizer, AbbVie, Express Scripts and Thermo Fisher
PR Newswire - Thu Sep 04, 8:20AM CDT
Today, Analysts Review released its research reports regarding Gilead Sciences, Inc. (NASDAQ: GILD), Pfizer Inc. (NYSE: PFE), AbbVie Inc. (NYSE: ABBV), Express Scripts Holding Company (NASDAQ: ESRX) and Thermo Fisher Scientific Inc. (NYSE: TMO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6210-100free.
Exact Sciences Corp. (EXAS) in Focus: Stock Rises 6.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 04, 7:51AM CDT
Exact Sciences Corporation (EXAS) was a big mover last session, as its shares rose over 6% on the day.
3 Reasons Gilead Sciences, Inc.’s Stock Could Fall
Brian Orelli, The Motley Fool - Motley Fool - Thu Sep 04, 7:31AM CDT
Gilead Sciences ' stock is a trading at all-time highs, up more than 80% over the last year on the back of a very successful launch of the company's hepatitis C drug Sovaldi. A few weeks ago, I shared three reasons Gilead's stock could go even...
Roche's Cobas 6800/8800 Testing Systems Launched - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 03, 5:55PM CDT
Roche (RHHBY) announced that its cobas 6800/8800 systems -- two integrated and fully automated molecular testing systems for blood and plasma donor screening are commercially available in markets which accept the CE mark.
Infinity Pharma (INFI) Shares Skyrocket on Cancer Drug Partnership - Stocks in the News
Zacks Research Staff - Zacks Investment Research - Wed Sep 03, 5:47PM CDT
Shares of Infinity Pharma (INFI) are up more than 40 percent thanks to news of a partnership with AbbVie for a new cancer drug.
Sanofi Reports Positive Phase III Data on Dengue Vaccine - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 03, 5:40PM CDT
Sanofi (SNY) announced that a phase III efficacy study on its dengue vaccine candidate has met the primary endpoint.
New Managers Revive Thrivent Large Cap Growth Fund
at Investor's Business Daily - Wed Sep 03, 5:28PM CDT
Thrivent Large Cap Growth is a reminder of how new managers can herald a change in a mutual fund's fortune. David Francis and Darren Bagwell, now co-managers, took the helm of the $521 million portfolio on Oct. 1, 2011. In the three years prior to...
Three Stocks Top-Performing Funds Like: Facebook Baidu Gilead
at Investor's Business Daily - Wed Sep 03, 5:28PM CDT
The new buys list of top-performing funds the past three months showed some heavy buying of top-rated stocks. The nation's leading funds have been stocking up on medical issues, which fared well as the market resumed its uptrend in August. Large...
Arena Pharmaceuticals' APD811 Gets Orphan Drug Status - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 03, 4:20PM CDT
Arena Pharmaceuticals, Inc. announced that its pulmonary arterial hypertensioncandidate APD811 has received orphan drug status from the FDA.
